New Age Alpha Advisors LLC Invests $1.89 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

New Age Alpha Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,678 shares of the company’s stock, valued at approximately $1,886,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. R Squared Ltd acquired a new position in Medpace during the 4th quarter valued at approximately $30,000. SBI Securities Co. Ltd. acquired a new position in shares of Medpace in the 4th quarter valued at $31,000. Jones Financial Companies Lllp raised its stake in Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC raised its stake in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after acquiring an additional 29 shares during the last quarter. Finally, True Wealth Design LLC lifted its position in Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after acquiring an additional 168 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Performance

MEDP opened at $312.36 on Monday. The company has a fifty day moving average of $335.90 and a two-hundred day moving average of $339.18. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The stock has a market capitalization of $9.52 billion, a price-to-earnings ratio of 24.73, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MEDP. Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Leerink Partners initiated coverage on shares of Medpace in a report on Monday, March 24th. They issued a “market perform” rating and a $330.00 price target on the stock. Finally, Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research note on Monday, March 24th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.